Dernières nouvelles pour argenx (NASDAQ:ARGX) Stock

argenx

Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.

argenx SE

Barclays analyst Eddie Kim downgrades Valaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAL#NYSE">VAL</a>) from Overweight to Equal-Weight and lowers the price target from $59 to $49.

News

Downgrades

Price Target

Analyst Ratings

Barclays Downgrades Valaris to Equal-Weight, Lowers Price Target to $49

HC Wainwright &amp; Co. analyst Vernon Bernardino reiterates Candel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) with a Buy and raises the price target from $11 to $19.

Reiteration

CADL

HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Raises Price Target to $19

BTCM

BIT Mining Receives NYSE Letter That It Regained Compliance With Quantitative Continued Listing Standards

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) with a Buy and maintains $221 price target.

KRYS

HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $221 Price Target

Barclays analyst David Anderson downgrades Halliburton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) from Overweight to Equal-Weight and lowers the price target from $43 to $33.

Barclays Downgrades Halliburton to Equal-Weight, Lowers Price Target to $33

Under the agreement, Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535. Hansoh Pharma will receive an upfront payment of $112 million and is eligible to receive up to $1.9 billion in milestone payments associated with the development, regulatory approval and commercialization of the candidate, as well as royalties on sales.
Hansoh Pharma may co-promote or solely commercialize HS-10535 in China subject to certain conditions. Merck will record a pre-tax charge of $112 million, or $0.04 per share, to be included in GAAP and non-GAAP results in the fourth quarter of 2024.

Merck, Hansoh Pharma Enter Exclusive Global License Agreement For HS-10535, An Investigational Preclinical Oral Small Molecule GLP-1 Receptor Agonist; Hansoh To Receive An Upfront Payment Of $112M And Up To $1.9B In Milestones

Needham analyst Laura Martin reiterates Taboola.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBLA#NASDAQ">TBLA</a>) with a Buy and maintains $5 price target.

TBLA

Needham Reiterates Buy on Taboola.com, Maintains $5 Price Target

JP Morgan analyst Cory Carpenter maintains Take-Two Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) with a Overweight and raises the price target from $195 to $225.

TTWO

JP Morgan Maintains Overweight on Take-Two Interactive, Raises Price Target to $225

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates PDS Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) with a Buy and maintains $21 price target.

PDSB

HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $21 Price Target

JP Morgan analyst David Karnovsky downgrades PLAYSTUDIOS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYPS#NASDAQ">MYPS</a>) from Neutral to Underweight.

MYPS

JP Morgan Downgrades PLAYSTUDIOS to Underweight

Needham analyst Scott Berg reiterates Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) with a Buy and maintains $375 price target.

Needham Reiterates Buy on Salesforce, Maintains $375 Price Target

JP Morgan analyst Doug Anmuth downgrades Angi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGI#NASDAQ">ANGI</a>) from Overweight to Neutral.

ANGI

JP Morgan Downgrades Angi to Neutral

UMC will purchase more than 30 billion kilowatt-hours of power from Fengmiao I over least 30 years.
&nbsp;This agreement will help UMC achieve its goal of 50% renewable energy use by 2030 as part of the company's roadmap to net zero emissions and 100% renewable energy by 2050.

United Microelectronics Inks 30-Year, 30B kWh Offshore Wind Power Agreement  With Fengmiao I

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates ALX Oncology Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>) with a Buy and maintains $25 price target.

ALXO

HC Wainwright & Co. Reiterates Buy on ALX Oncology Holdings, Maintains $25 Price Target

JP Morgan analyst Cory Carpenter downgrades Getty Images Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GETY#NYSE">GETY</a>) from Neutral to Underweight.

GETY

JP Morgan Downgrades Getty Images Holdings to Underweight

The engagement with an EU-based GMP manufacturing facility enables timely production and preparation for clinical trial. The EU-based GMP manufacturer has large-scale commercial production capabilities, to support Polyrizon in future commercialization efforts

PLRZ

Polyrizon Secures GMP Manufacturing Partnership With Eurofins CDMO Amatsiaquitaine, Advancing Toward PL-14 Allergy Blocker Clinical Trial In 2025

CMPS

Compass Pathways Common Stock To Be Added To The Nasdaq Biotechnology Index

JP Morgan analyst Cory Carpenter upgrades Xometry (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XMTR#NASDAQ">XMTR</a>) from Neutral to Overweight and raises the price target from $25 to $45.

Upgrades

XMTR

JP Morgan Upgrades Xometry to Overweight, Raises Price Target to $45

JP Morgan analyst Cory Carpenter downgrades Match Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) from Overweight to Neutral and lowers the price target from $40 to $33.

MTCH

JP Morgan Downgrades Match Group to Neutral, Lowers Price Target to $33

Jefferies analyst Andrew Tsai initiates coverage on Rocket Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>) with a Buy rating and announces Price Target of $29.

Initiation

RCKT

Jefferies Initiates Coverage On Rocket Pharmaceuticals with Buy Rating, Announces Price Target of $29

JPMorgan analyst James Gordon raised the firm's price target on Argenx (ARGX) to EUR 740 from EUR 620 and keeps an Overweight rating on the shares....

Argenx price target raised to EUR 740 from EUR 620 at JPMorgan

European stocks will see downtrend mid-year 2025 before recovery

Genmab Is Too Attractive To Ignore

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arcellx Inc (ACLX – Research Report), Argenx Se (ARG...

Analysts Offer Insights on Healthcare Companies: Arcellx Inc (ACLX), Argenx Se (ARGX) and Keros Therapeutics (KROS)

Tracking Baker Brothers Portfolio - Q3 2024 Update

In a report released today, Samantha Semenkow from Citi maintained a Buy rating on Argenx Se (ARGX – Research Report), with a price target of $681....

Citi Reaffirms Their Buy Rating on Argenx Se (ARGX)

American Century Focused Dynamic Growth Fund Q3 2024 Commentary

In a report released yesterday, Alex Thompson CFA from Stifel Nicolaus maintained a Buy rating on Argenx Se (ARGX – Research Report), with a price ...

Stifel Nicolaus Keeps Their Buy Rating on Argenx Se (ARGX)

Leerink Partners analyst Thomas Smith maintained a Buy rating on Argenx Se (ARGX – Research Report) yesterday and set a price target of $635.00. Th...

Argenx Se: Promising Growth with Strategic Expansion and Clinical Advancements

In a report released today, Xian Deng from UBS maintained a Hold rating on Argenx Se (ARGX – Research Report), with a price target of $600.00. The ...

Argenx Se (ARGX) Gets a Hold from UBS

AAPL

ABCL

ACAD

ACLX

ALAB

ALGS

ALKS

ALNY

ALSMY

AMBP

AMZN

ARGNF

ARGX

AVTE

BCYC

BEIGF

BGNE

BILL

BMEA

BNTX

CAVA

CERS

CTTAY

DNLI

EWTX

FLUT

GLUE

GMAB

GOOG

GOOGL

HOOK

ICAGY

IGMS

IMCR

IMTX

INCY

INSM

KALA

KNSA

KNSL

KROS

KYMR

MDGL

MSFT

MTLS

MTUAY

NAMS

NFLX

NRIX

NVDA

OKTA

PROSY

RARE

REGN

REPL

RKLB

ROIV

RVMD

RYTM

SGMT

SIEGY

SMMT

SRAD

STOK

TCRX

TRDA

TSLA

TSVT

VEON

VTVT

Press Releases

argenx to Present at Upcoming Investor Conferences

argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy

argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions

argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024

argenx Reports Third Quarter 2024 Financial Results and Provides Business Update

argenx to Participate at Upcoming Investor Conferences

Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China

argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China

argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

Comments

argenx

Actualités

Dernières nouvelles pour argenx (NASDAQ:ARGX) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL